New York, June 4, 2026, 04:17 EDT
- Prelude Therapeutics last traded at $3.66, up 19 cents, or roughly 5.4%, from its previous close, ahead of Thursday’s regular Nasdaq open.
- Prelude Therapeutics was at the Jefferies Global Healthcare Conference on Wednesday. The company is also set to attend Goldman Sachs’ healthcare event next week.
Prelude Therapeutics shares traded higher in premarket action Thursday, after the cancer-drug maker showed up at an investor event in New York on Wednesday. The move brought the stock back into focus for traders.
Prelude last traded at $3.66 for a market cap near $302 million. The SPDR S&P Biotech ETF was up 1.6% in its latest trade. The iShares Nasdaq Biotechnology ETF gained 2.0%.
Why it matters now: Prelude’s valuation leans on how much confidence investors have in two key pipeline events rather than its sales. One is a Phase 1 trial, the start of human testing, for PRT12396. The other is an investigational new drug application, or IND, for PRT13722. An IND is what companies file with the U.S. Food and Drug Administration to start human trials. In its May investor deck, Prelude said PRT12396 was “Phase 1 now enrolling.” It gave a mid-2026 IND filing goal for PRT13722.
Prelude’s investor schedule is packed. The Jefferies fireside chat was set for June 3 at 12:15 p.m. EDT. Next up, the company has the Goldman Sachs healthcare conference listed for June 10 at 11:20 a.m. EDT.
Prelude’s main JAK2V617F program is aimed at treating myeloproliferative neoplasms, a type of blood cancer where the bone marrow produces too many blood cells. This is a mutant-selective drug, built to target cells with the mutation tied to the disease and leave normal cells mostly untouched.
Incyte is in the picture here. A quarterly filing disclosed that Incyte holds exclusive rights to buy Prelude’s JAK2V617F JH2 inhibitor program for $100 million, on top of a prior $35 million upfront. Prelude stands to get up to $775 million more in milestones and royalties if things move forward.
Incyte shows up as both a competitor and a partner in this space. Prelude’s investor deck set its strategy against approved JAK inhibitors like ruxolitinib, which is sold as Jakafi. The company said drugs on the market right now can affect both mutated and normal JAK2, sometimes causing dose-related side effects like low platelets and anemia or hitting red blood cell counts.
Prelude is also watching PRT13722, its KAT6A degrader for ER-positive breast cancer. In these cancers, estrogen drives tumor growth, and a degrader aims to remove the disease-linked protein. The company said it plans to begin a Phase 1 trial in the second half of 2026, if it gets clearance.
Prelude CEO Kris Vaddi said in May the company moved PRT12396 into first-in-human studies and pushed its cash runway out to the second quarter of 2028. Cash runway means how long the company can keep operating with the cash on hand.
Prelude Chief Scientific Officer Peggy Scherle said in April PRT13722 may have an “improved hematological safety profile” and offer “meaningful combination approaches” alongside breast-cancer therapies. Edith A. Perez, professor emeritus at Mayo Clinic and a strategic clinical adviser to Prelude, said there is still a “significant unmet need” in breast cancer, and that it is important to “follow the science” as drugs like PRT13722 head toward the clinic. GlobeNewswire
Prelude is running with a thinner cushion than last year. The biotech posted a first-quarter net loss of $10.4 million, improving from a $32.1 million loss a year before, according to its 10-Q. Cash, restricted cash and marketable securities stood at $84.8 million as of March 31. Prelude hasn’t reported any product revenue yet, the filing said, and losses have stacked up since the company started.
Clinical execution remains a key risk. In its own presentation, Prelude notes its drugs are still being studied, are not FDA approved, and have yet to prove safety or effectiveness in the areas being researched. Slow enrollment, any safety issue, or soft initial data could turn the stock fast, since the current move is tied more to pipeline timelines than sales of approved products.
Prelude investors this week are waiting to see if management offers more on enrollment numbers, dosing plans, or the KAT6A IND timing at the Goldman Sachs event. The setup hasn’t changed much: shares have already moved, cash runway is in place, but clinic data still needs to deliver the next real evidence.
